Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Dr Passaro on the Role of MET in Guiding Treatment Strategies After EGFR TKI Progression in NSCLC

October 16th 2025

Antonio Passaro, MD, PhD, discusses testing methodologies and clinical trials for MET, the most studied resistance biomarker, following progression on EGFR TKIs.

Dr Le on the Prevalence of EGFR PACC Mutations in NSCLC

October 15th 2025

Xiuning Le, MD, PhD, discusses the prevalence of EGFR PACC mutations in NSCLC.

Key Areas of Ongoing Research in MDS

October 15th 2025

Guillermo Garcia-Manero, MD, discusses ongoing research to watch in MDS.

Navigating Second-Line Treatment Decisions in Lower-Risk MDS

October 15th 2025

Guillermo Garcia-Manero, MD, discusses second-line treatment decision-making in lower-risk MDS.

FDA Approval of TAR-200 Represents Potential Bladder-Sparing Option in BCG-Unresponsive NMIBC

October 15th 2025

Joseph Jacob, MD, MCR, discusses the significance of the FDA approval of TAR-200 for BCG-unresponsive non–muscle-invasive bladder cancer.

Dr Lynam on the Importance of FRα Expression Testing in Ovarian Cancer

October 15th 2025

Sarah Lynam, MD, highlights the importance of folate receptor–alpha expression testing to inform treatment decision-making in patients with ovarian cancer.

Dr Lee on the Role of IMRT in Locally Advanced NSCLC Management

October 14th 2025

Percy Lee, MD, discusses the importance of considering radiation therapy techniques like IMRT and proton therapy for patients with locally advanced NSCLC.

Niraparib Plus AAP Could Represent New Standard Option for mCSPC With HRR Gene Alterations

October 14th 2025

The AMPLITUDE trial met its primary end point of rPFS with niraparib regimen vs placebo in metastatic castration-sensitive prostate cancer.

Baseline Cardiovascular Assessment, Monitoring Are Crucial With BTK Inhibitors in CLL and Other Hematologic Malignancies

October 14th 2025

A meta analysis found BTK inhibitors carry risks of hypertension, atrial fibrillation, and hemorrhage, underscoring the need for cardiovascular monitoring.

Countdown to ESMO 2025: Catch Up on OncLive’s Extensive Tumor-Specific Previews

October 13th 2025

Preview the top lung, breast, GI, GU, gynecologic, and hematologic oncology abstracts and topics ahead of the 2025 ESMO Congress.

Ficerafusp Alfa Earns FDA Breakthrough Therapy Designation for HPV-Negative, Recurrent/Metastatic HNSCC

October 13th 2025

The FDA granted breakthrough therapy designation to ficerafusp alfa plus pembrolizumab for metastatic/recurrent head and neck squamous cell carcinoma.

FDA Grants Breakthrough Therapy Designation to Sonrotoclax for R/R Mantle Cell Lymphoma

October 13th 2025

The FDA granted breakthrough therapy designation to sonrotoclax for relapsed/refractory mantle cell lymphoma.

Navigating Immunotherapy in Advanced NSCLC After Early-Stage IO Therapy

October 13th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss the use of immunotherapy after prior immunotherapy for early-stage NSCLC.

Dr Jain on Treatment Decision-Making With JAK Inhibitors in Myelofibrosis

October 13th 2025

Akriti G. Jain, MD, details the treatment decision-making of JAK inhibitors for the treatment of patients with myelofibrosis.

5-Year EMPOWER-Lung 3 Data for Cemiplimab Plus Chemo in Advanced NSCLC

October 13th 2025

Eric K. Singhi, MD, and Sandip P. Patel, MD, discuss 5-year data for cemiplimab plus chemotherapy in advanced NSCLC.

Removal of REMS Requirements Could Help Streamline CAR T-Cell Therapy Access in Hematologic Cancer Care

October 10th 2025

The removal of REMS programs for approved CAR T-cell therapies could enable improved access and streamlined management of hematologic malignancies.

Real-World Evidence Complements Randomized Clinical Trial Data in Colorectal Cancer

October 10th 2025

Three experts share their perspectives on the complementary relationship between randomized clinical trials and real-world evidence in colorectal cancer.

FDA Grants Orphan Drug Designation to Cintredekin Besudotox in Glioblastoma

October 10th 2025

The regulatory agency has granted orphan drug designation to cintredekin besudotox for the treatment of patients with glioblastoma.

OST-HER2 Displays Potential OS Benefit in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

October 10th 2025

OST-HER2 produced a potential overall survival benefit at 2 years in recurrent, fully resected, pulmonary metastatic osteosarcoma.

OncLive Poll Results Reveal Most Anticipated GI Cancer Abstracts and Subtypes Ahead of ESMO 2025

October 10th 2025

See poll results highlighting the top gastrointestinal oncology abstracts and subtypes to watch at the 2025 ESMO Congress.